Terms: = Ovarian cancer AND TFRC, P02786, 7037, ENSG00000072274, TFR1, CD71 AND Treatment
10 results:
1. Long term pregnancy outcomes of women with cancer following fertility preservation: A systematic review and meta-analysis.
Xu Z; Ibrahim S; Burdett S; Rydzewska L; Al Wattar BH; Davies MC
Eur J Obstet Gynecol Reprod Biol; 2023 Feb; 281():41-48. PubMed ID: 36535069
[TBL] [Abstract] [Full Text] [Related]
2. Efficient iron utilization compensates for loss of extracellular matrix of ovarian cancer spheroids.
Wang Q; Gu T; Ma L; Bu S; Zhou W; Mao G; Wang LL; Guo Y; Lai D
Free Radic Biol Med; 2021 Feb; 164():369-380. PubMed ID: 33450374
[TBL] [Abstract] [Full Text] [Related]
3. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract] [Full Text] [Related]
4. Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding.
Peng H; Jin H; Zhuo H; Huang H
Oncotarget; 2017 Jul; 8(28):45597-45611. PubMed ID: 28484093
[TBL] [Abstract] [Full Text] [Related]
5. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.
Shigeta S; Toyoshima M; Kitatani K; Ishibashi M; Usui T; Yaegashi N
Oncogene; 2016 Jul; 35(27):3577-86. PubMed ID: 26549031
[TBL] [Abstract] [Full Text] [Related]
6. Iron alters cell survival in a mitochondria-dependent pathway in ovarian cancer cells.
Bauckman K; Haller E; Taran N; Rockfield S; Ruiz-Rivera A; Nanjundan M
Biochem J; 2015 Mar; 466(2):401-13. PubMed ID: 25697096
[TBL] [Abstract] [Full Text] [Related]
7. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract] [Full Text] [Related]
8. Differences in the intracellular fate of free and polymer-bound doxorubicin.
Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B
J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391
[TBL] [Abstract] [Full Text] [Related]
9. Ascitic fluid-associated lymphocytes in patients with metastatic ovarian cancer. Analysis of lymphocyte subsets and of phenotypical changes induced by "in vitro".
Loiudice L; Dell'Osso A; Loria MP; D'Ambra PP; Lasaracina E; Crollo E; Lucivero G
Eur J Gynaecol Oncol; 1995; 16(4):301-6. PubMed ID: 7556288
[TBL] [Abstract] [Full Text] [Related]
10. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract] [Full Text] [Related]
